Contact Us |
Cellular Immunotherapy Data Resource
By Marcelo Pasquini, MD, MS
The CIBMTR launched the Cellular Therapy Registry in the summer of 2016. Since then, the CIBMTR received data from >200 centers for >2,000 patients who received cellular therapy. The registry includes patients who received cellular immunotherapy for cancer, including >600 patients who received CAR T cell therapy. The registry also includes patients who received cellular therapy for regenerative medicine indications (>200) and cellular therapies administered as either part or for treatment of complications of HCT, such as donor cellular infusions (>1,200).
In September 2018, the CIBMTR received funding from the National Cancer Institute to serve as the Cellular Immunotherapy Data Resource (CIDR). The CIDR was developed to support the biomedical community and the Immuno-Oncology Transplantation Network (IOTN). Both the IOTN and the CIDR are part of the Cancer MoonshotSM initiative to accelerate cancer research and make more therapies available to more patients.
The goal of the CIDR is to provide the academic community, as well as relevant pharmaceutical partners, with an infrastructure for collection of high-quality data. Data include patient demographics, tumor characteristics, course of cancer treatment, cellular product manufacturing details, toxicity, and outcomes. The CIDR includes patients who received cellular immunotherapy for cancer as part of clinical trials as well as those treated with FDA-approved agents.
The CIDR relies on the CIBMTR Cellular Therapy Registry infrastructure; however, it requires an independent governance structure to fulfill the objectives outlined in the program to interact with the IOTN and other stakeholders. The CIDR Executive Committee was created to provide oversight to all activities related to this program.
The CIDR governance structure included the development of a working committee to oversee the utilization of data for research purposes. The CIBMTR re-organized its current scientific working committee structure to create the Cellular Immunotherapy for Cancer Working Committee. (See next article for more information.) The CIBMTR Advisory Committee will share oversight responsibilities of this new working committee to provide the same performance metrics currently in place for all working committees.
The CIDR and its interaction with the IOTN and other Cancer Moonshot initiative programs represents an outstanding opportunity for the CIBMTR to expand its collaborations in research and maximize the utilization of this resource.
Return to Top
Cellular Immunotherapy for Cancer and Non-Malignant Diseases Working Committees
By Mary Eapen, MBBS, MS
The purpose of the CIBMTR's 15 Scientific Working Committees is to solicit input from the transplantation and cellular therapy community regarding how data submitted by the community is used to address important issues that will advance the field. Working Committees provide valuable insight regarding the issues the community thinks are most important, and they provide a broad range of expertise to guide CIBMTR studies to ensure they are of high scientific merit.
Working Committees are organized by subject area to reasonably distribute the workload, both statistically and administratively. With the recent award of the CIDR U24 grant, the CIBMTR re-organized the workload of two Working Committees.
The former Autoimmune Diseases and Cellular Therapies Working Committee is now the
Cellular Immunotherapy for Cancer Working Committee. This committee will focus on the role of cellular therapy for cancer. Autoimmune diseases are being moved to a newly formed
Non-Malignant Diseases Working Committee, which will replace the Primary Immune Deficiencies, Inborn Errors of Metabolism, and Other Non-Malignant Marrow Disorders Working Committee. The
Non-Malignant Diseases Working Committee will have primary responsibility for studying the role of HCT and cellular therapy, and in particular gene therapy, for non-malignant diseases.
Non-Malignant Diseases Working Committee will incorporate five broad disease groups:
As its mission, the
Non-Malignant Diseases Working Committee will study HCT and all modalities of cellular therapy as a curative treatment option within each disease or broad non-malignant disease group.
The inaugural TCT Meetings of ASBMT & CIBMTR were held at the Hilton Americas - Houston and George R. Brown Convention Center in Houston, Texas, Feb. 20-24 and boasted 4,055 registered attendees. We had the highest international representation in BMT Tandem / TCT Meetings history, with 45 countries represented. Countries with the highest attendance included the US, Canada, Brazil, Japan, Germany, Australia, and China.
Eighty-three participants took advantage of the TCT Meetings live stream. These individuals also had the opportunity to earn continuing education credits.
Program Co-Chairs Jane Apperley, MBChB, MD, and Gay Crooks, MBBS, along with the Scientific Organizing Committee put together an excellent program this year of 5 plenary sessions and 9 concurrent sessions. The meeting also included 3 breakfast symposia and 4 luncheon symposia, 13 oral abstract sessions with 90 abstracts presented, 7 product theaters, 2 poster sessions, 15 CIBMTR Working Committee meetings, 8 ASBMT Special Interest Group meetings, and 6 Meet-the-Professor sessions. In addition to an outstanding scientific program, parallel sessions were held for administrative directors, BMT CTN coordinators and investigators, clinical research professionals and data managers, information technologists, nurse practitioners, pediatric providers, pharmacists, and transplant nurses.
CIBMTR Distinguished Service Award: WBMT
The CIBMTR collaborates with the global scientific community to advance HCT and cellular therapy research worldwide. The purpose of the Distinguished Service Award is to recognize individuals who have made outstanding contributions to the CIBMTR's research mission in one or more of the following areas: Promoting HCT research and clinical care in developing countries, advancing the field despite unique challenges, expanding the availability of transplantation, disseminating research results to clinicians and patients to improve outcomes and quality of life, and collaboration with organizations to increase data exchange and research collaboration worldwide.
ASBMT Lifetime Achievement Award: Helen Heslop, MD
ASBMT recognizes an individual who has made continuing contributions to the field of HCT, either in basic biology or clinical application.
ASBMT Public Service Award: Jeff Haertling
ASBMT recognizes an individual outside of its membership who has advanced the interests of HCT or given special service to the patients and families they serve.
Mortimer M. Bortin Lecture: Paul Martin, MD -
Treatment of chronic graft-versus-host disease: Progress to data and challenges ahead
The Mortimer M. Bortin Lecture commemorates the Founding Scientific Director of the International Bone Marrow Transplant Registry (IBMTR, forerunner of the CIBMTR), whose foresight and dedication were critical to the development of the CIBMTR as a global resource of HCT research. Lecturers are chosen based on their contributions to our understanding of graft-versus-tumor effects and/or the advancement of clinical HCT research.
E. Donnall Thomas Lecture: Stephen Forman, MD -
CMV: From lethal transplantation complication to potential anticancer therapeutic vaccine
In honor of Dr. Thomas, the E. Donnall Thomas Lecture recognizes an eminent physician or scientist, either a clinician or investigator, who has contributed meritoriously to the advancement of HCT knowledge.
Several networking opportunities were offered as part of the scientific program, including two poster sessions, a networking reception in the exhibit hall, and the TCT Meetings Reception.
During the 2019 TCT Meetings, ASBMT announced the Board of Directors' recommended change of the society's name to the American Society for Transplantation and Cellular Therapy (ASTCT). The ASTCT name was chosen to acknowledge the rapid shift toward cellular therapies and to reflect the organization's 25 years of leadership in that field, along with transplantation. ASTCT is the professional home and community for healthcare providers, researchers, and other professionals who are dedicated to cures involving transplantation and cellular therapy.
Watch for details on the 2020 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR in the coming months. Contact Sherry Fisher at
TCTMeetings@mcw.edu for information regarding support opportunities for next year's meeting.
On behalf of the TCT Meetings Planning Team and the 2020 Scientific Organizing Chairs, Mary Flowers, MD, and Katy Rezvani, MD, PhD, we look forward to seeing you at the Marriott World Center in Orlando, Florida, February 19-23.
Join the conversation: #TCTM20
Return to Top
The CIBMTR is pleased to announce a new Center Support Model that enables us to deliver a more flexible and service-oriented experience for centers.
The platform, ServiceNow, replaces our current process for how you receive assistance from your assigned CRC.
The new Center Support Model will deploy on
Wednesday, May 22, 2019. At that time, we will provide you with the link to ServiceNow.
Customer Service: Quality of customer service will increase with more transparency and improved turnaround time
CRCs: Centers will no longer be assigned to a single CRC except for centers who have a CPI suspension or probation, failed audit, have new data managers, or are brand-new centers
Self-Service: All questions and requests for customer service will be entered in a single location, making it easier for centers to manage. ServiceNow will offer a robust self-service capability with everything in one spot, including:
The ability to ask a question or make a request
Reporting: The CIBMTR will have the ability to track metrics and see trending questions or concerns, allowing us to proactively make beneficial changes to the system or processes.
TCT Presentation: The new Center Support Model presented during the CRP/Data Management Conference on February, 20 2019, will be posted on the
CIBMTR website. This recording will be available 6-8 weeks after TCT.
Lunch & Learns: Prior to Go-Live, the CIBMTR will schedule several Lunch & Learn sessions via WebEx to review how centers may utilize the new system.
Go-Live: A Go-Live Command Center will be based out of the Minneapolis campus May 22-24, 2019, to provide additional support.
Please contact Eileen Tuschl (email@example.com) or Angela Hauck (firstname.lastname@example.org) with any questions regarding the new Center Support Model implementation.
Three new patient-level summaries of CIBMTR research publications are now available on the
Study Summaries for Patients webpage:
Tailoring care plans for life long after transplant
A survivorship care plan includes possible health issues that can happen months and years after BMT, plus ways to watch for and prevent them.
BMT in childhood linked with higher jobless rate in adulthood
In the US, survivors had unemployment rates of about 15%. Survivors who had BMT outside the US had even higher rates.
Survivorship care plans help transplant survivors
Survivorship care plans helped survivors of blood or marrow transplant have a better quality of life, according to a study.
Summaries are created through a collaborative process involving CIBMTR Consumer Advocacy Committee members, CIBMTR Medical Writers and Communications Specialist; NMDP/Be The Match Patient Education Specialists, and CIBMTR Scientific Directors. Developing these summaries is one of the main initiatives of the Consumer Advocacy Committee.
The Consumer Advocacy Committee was created in 2005 as a subcommittee of the Advisory Committee to communicate CIBMTR research results and data to the non-medical community and to provide patient and donor perspectives during the development of the CIBMTR research agenda. Many members have personal experience as a donor, recipient, or family member.
Like us on Facebook and follow us on Twitter to stay up-to-date with important news and events. We promote our publications, share important content from other organizations, and publicize our key meetings and events. Follow us today!
The CIBMTR is supported primarily by Public Health Service Grant / Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant / Cooperative Agreement 1U24HL138660 from NHLBI and NCI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); Grants N00014-17-1-2388, N00014-17-1-2850 and N00014-18-1-2045 from the Office of Naval Research HHSH250201700006C; and grants from our
corporate and private contributors.
Need an acronym defined? Review our
list of common abbreviations.